Physician

Andrew Mcmorris Iliff, MD

According to 2025 Medicare claims, Andrew Iliff, MD (NPI: 1851654818) practices hematology/oncology in the Columbia, MO market, with the plurality of this provider's patient population coming from Boone, MO. This provider's primary affiliated billing organization is MISSOURI CANCER ASSOCIATES LLC (NPI: 1215947338; TIN: 431763016) and primary practice location at 65201-7167. Iliff is affiliated with the Aledade 98 MO MSSP Enhanced (ACO ID: A4998) and Aledade 93 National MSSP Enhanced (ACO ID: A5206), participating under the MSSP model.

Iliff's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,155 traditional Medicare patients, billed 286,054 HCPCS/CPT codes, and received $5,236,817 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 3,195 prescription claims across 426 beneficiaries totaling $5,486,597 in drug costs, led by Revlimid (Lenalidomide). DME data shows 65 claims. Open Payments data shows 249 records totaling $4,162. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,911,120 to $5,236,817. Similarly, Part D prescription costs have moved sharply higher in recent years, from $28,451 to $5,486,597. In contrast, DME billing represents a smaller volume and rose steadily, from $0 to $3,018.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	743	141,014	$1,911,120
2019	991	285,079	$3,652,733
2020	998	321,614	$4,362,616
2021	1,178	375,773	$5,090,796
2022	1,201	460,658	$5,213,676
2023	1,172	353,889	$4,222,364
2024	1,155	286,054	$5,236,817

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	40	117	$28,451
2016	24	86	$9,982
2017	N/R	18	$2,142
2018	216	948	$691,659
2019	299	2,769	$2,648,400
2020	322	3,160	$3,727,193
2021	371	3,222	$5,538,499
2022	406	3,268	$6,272,626
2023	416	2,798	$4,551,666
2024	426	3,195	$5,486,597

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$25
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	50	$6,729
2019	11	71	$7,511
2020	N/R	55	$3,581
2021	N/R	88	$6,606
2022	N/R	98	$2,775
2023	N/R	120	$10,558
2024	N/R	65	$2,020

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	237	572	$87
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	380	974	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	298	370	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	435	893	$12
96372	Injection of drug or substance under skin or into muscle	197	331	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	49	1,372	$926,431
Pomalyst	Pomalidomide	25	700	$547,759
Erleada	Apalutamide	43	1,290	$511,357
Ibrance	Palbociclib	29	812	$453,849
Brukinsa	Zanubrutinib	25	750	$314,072

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	19	$1,047
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$427
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$188

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	249	$4,162	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Mcmorris Iliff, MD?

Tedicare shows public-source Medicare data for Andrew Mcmorris Iliff, MD (NPI 1851654818), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Mcmorris Iliff, MD have ACO affiliation data?

Andrew Mcmorris Iliff, MD is shown with ACO affiliation data for Aledade 98 MO MSSP Enhanced (MSSP, ACO ID A4998) and Aledade 93 National MSSP Enhanced (MSSP, ACO ID A5206).

What billing organization is linked to Andrew Mcmorris Iliff, MD?

Andrew Mcmorris Iliff, MD is linked to MISSOURI CANCER ASSOCIATES LLC (billing NPI 1215947338) in the available physician profile data.

Does Andrew Mcmorris Iliff, MD have Open Payments data?

Andrew Mcmorris Iliff, MD has 249 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.